Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To assess the dynamic uptake and washout of 123-I CLINDE, a potential imaging biomarker for
inflammatory changes in brain, using single photon emission computed tomography (SPECT) in
similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).
To perform blood metabolite characterization of 123-I CLINDE in healthy and subjects with AD
or PD to determine the nature of metabolites in assessment of 123-I CLINDE as a single photon
computed tomography (SPECT) brain imaging agent.
Evaluate the test/retest reproducibility of 123-I CLINDE, and SPECT in AD and PD subjects and
healthy controls